transplantologiyaТрансплантологияTransplantologiya. The Russian Journal of Transplantation2074-05062542-0909IPO Association of Transplantologists10.23873/2074-0506-2022-14-4-462-475transplantologiya-708Research ArticleОБЗОРНЫЕ СТАТЬИ И ЛЕКЦИИREVIEW ARTICLES AND LECTURESТ-регуляторные клетки и трансплантация аллогенных гемопоэтических стволовых клетокRegulatory T-cells and allogeneic hematopoietic stem cell transplantationhttps://orcid.org/0000-0001-8158-8210КараваеваО. С.KaravaevaO. S.

Ольга Станиславовна Караваева, аспирант, врач-гематолог 

125167, Москва, Новый Зыковский пр-д, д. 4

Olga S. Karavaeva, Postgraduate, Hematologist

Noviy Zykovskiy Dr., Moscow 125167 

olga.starikova.1994@mail.ruhttps://orcid.org/0000-0001-9431-8316ДроковМ. Ю.DrokovM. Yu.

Михаил Юрьевич Дроков, канд. мед. наук, врач-гематолог, руководитель сектора научных исследований химиотерапии гемобластозов, депрессий кроветворения и трансплантации костного мозга

125167, Москва, Новый Зыковский пр-д, д. 4

Mikhail Yu. Drokov, Cand. Sci. (Med.), Hematologist, Head of the Sector for Scientific Research in Chemoblastosis Chemotherapy, Hematopoietic Depressions, and Bone Marrow Transplantation

Noviy Zykovskiy Dr., Moscow 125167 

https://orcid.org/0000-0002-0110-3314ХамагановаЕ. Г.KhamaganovaE. G.

Екатерина Георгиевна Хамаганова, д-р биол. наук, иммуногенетик, заведующая лабораторией тканевого типирования

125167, Москва, Новый Зыковский пр-д, д. 4

Ekaterina G. Khamaganova, Dr. Sci. (Biol.), Immunogeneticist, Head of the Tissue Typing Laboratory

Noviy Zykovskiy Dr., Moscow 125167 

ФГБУ «НМИЦ гематологии» МЗ РФРоссияNational Medical Research Center for HematologyRussian Federation202220122022144462475Copyright © Караваева О.С., Дроков М.Ю., Хамаганова Е.Г., 20222022Караваева О.С., Дроков М.Ю., Хамаганова Е.Г.Karavaeva O.S., Drokov M.Y., Khamaganova E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jtransplantologiya.ru/jour/article/view/708

Статья посвящена обобщению имеющихся данных о Т-регуляторных клетках. Подробно описаны этапы их изучения, развитие, классификация, механизмы иммуносупрессии в общем понимании, а также в аспекте трансплантации аллогенных гемопоэтических стволовых клеток. Рассмотрено влияние иммуносупрессивных агентов на данную популяцию клеток. Раскрыта роль Т-регуляторных клеток в патогенезе как острой, так и хронической реакции «трансплантат против хозяина», а также подробно освещены возможности клинического применения Т-регуляторных клеток (в том числе модифицированных) в рамках профилактики и терапии данных осложнений.

The article has summarized the available data about regulatory T cells, describing in-detail the stages of their studying, their development, classification, mechanisms of immunosuppression in general terms and also in the context of allogeneic hematopoietic stem cells transplantation. The effect of immunosuppressive agents on this cell population is considered.

The role of regulatory T cells in the pathogenesis of both acute and chronic graft-versus-host disease has been revealed. The possibilities of clinical use of regulatory T cells (including modified regulatory T cells) in the prevention and treatment of these complications are described in detail.

Т-регуляторные клеткиТрегтрансплантация аллогенных гемопоэтических стволовых клетокострая реакция «трансплантат против хозяина»хроническая реакция «трансплантат против хозяина»regulatory T cellsTregallogeneic hematopoietic stem cell transplantationacute graft-versus-host diseasechronic graft-versus-host diseaseReferencesVignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523. PMID: 18566595 https://doi.org/10.1038/NRI2343Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523. PMID: 18566595 https://doi.org/10.1038/NRI2343Gershon RK, Kondo K. Infectious immunological tolerance. Immunology. 1971;21(6):903–914. PMID: 4943147Gershon RK, Kondo K. Infectious immunological tolerance. Immunology. 1971;21(6):903–914. PMID: 4943147Nishizuka Y. A novel experimental system of organ-localized autoimmune diseases in the mouse. Acta Pathol Jpn. 1982;32 Suppl 1:211–222. PMID: 6764999Nishizuka Y. A novel experimental system of organ-localized autoimmune diseases in the mouse. Acta Pathol Jpn. 1982;32 Suppl 1:211–222. PMID: 6764999Powrie F, Leach MW, Mauze S, Caddie LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993;5(11):1461–1471. PMID: 7903159 https://doi.org/10.1093/intimm/5.11.1461Powrie F, Leach MW, Mauze S, Caddie LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993;5(11):1461–1471. PMID: 7903159 https://doi.org/10.1093/intimm/5.11.1461Almeida ARM, Legrand N, Papiernik M, Freitas AA. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol. 2002;169(9):4850–4860. PMID: 12391195 https://doi.org/10.4049/jimmunol.169.9.4850Almeida ARM, Legrand N, Papiernik M, Freitas AA. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol. 2002;169(9):4850–4860. PMID: 12391195 https://doi.org/10.4049/jimmunol.169.9.4850Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–1061. PMID: 12522256 https://doi.org/10.1126/science.1079490Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–1061. PMID: 12522256 https://doi.org/10.1126/science.1079490Liu W, Putnam AL, Xu-yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701–1711. PMID: 16818678 https://doi.org/10.1084/jem.20060772Liu W, Putnam AL, Xu-yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701–1711. PMID: 16818678 https://doi.org/10.1084/jem.20060772Kalampokis I, Yoshizaki A, Tedder TF.IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 2013;15Suppl1(Suppl 1):S1. PMID: 23566714 https://doi.org/10.1186/ar3907Kalampokis I, Yoshizaki A, Tedder TF.IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 2013;15Suppl1(Suppl 1):S1. PMID: 23566714 https://doi.org/10.1186/ar3907Mishra S, Srinivasan S, Ma C, Zhang N. CD8+ regulatory T cell – a mystery to be revealed. Front Immunol. 2021;12: 708874. PMID: 34484208 https://doi.org/10.3389/FIMMU.2021.708874Mishra S, Srinivasan S, Ma C, Zhang N. CD8+ regulatory T cell – a mystery to be revealed. Front Immunol. 2021;12: 708874. PMID: 34484208 https://doi.org/10.3389/FIMMU.2021.708874Takahashi T, Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic selftolerance and preventing autoimmune disease. Curr Mol Med. 2003;3(8):693–706. PMID: 14682491 https://doi.org/10.2174/1566524033479429Takahashi T, Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic selftolerance and preventing autoimmune disease. Curr Mol Med. 2003;3(8):693–706. PMID: 14682491 https://doi.org/10.2174/1566524033479429Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18–32. PMID: 11722621 https://doi.org/10.1034/J.1600-065X.2001.1820102.XSakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18–32. PMID: 11722621 https://doi.org/10.1034/J.1600-065X.2001.1820102.XSaleh R, Elkord E. FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174–85. PMID: 32721551 https://doi.org/10.1016/J.canlet.2020.07.022Saleh R, Elkord E. FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174–85. PMID: 32721551 https://doi.org/10.1016/J.canlet.2020.07.022Dominguez-Villar M, Hafler DA. Regulatory T cells in autoimmune disease. Nat Immunol. 2018;19(7):665– 673. PMID: 29925983 https://doi.org/10.1038/S41590-018-0120-4Dominguez-Villar M, Hafler DA. Regulatory T cells in autoimmune disease. Nat Immunol. 2018;19(7):665– 673. PMID: 29925983 https://doi.org/10.1038/S41590-018-0120-4Schwarz BA, Bhandoola A. Trafficking from the bone marrow to the thymus: a prerequisite for thymopoiesis. Immunol Rev. 2006;209(1):47–57. PMID: 16448533 https://doi.org/10.1111/J.0105-2896.2006.00350.XSchwarz BA, Bhandoola A. Trafficking from the bone marrow to the thymus: a prerequisite for thymopoiesis. Immunol Rev. 2006;209(1):47–57. PMID: 16448533 https://doi.org/10.1111/J.0105-2896.2006.00350.XBaldwin TA, Hogquist KA, Jameson SC. The fourth way? Harnessing aggressive tendencies in the thymus. J Immunol. 2004;173(11):6515–6520. PMID: 15557139 https://doi.org/10.4049/JIMMUNOL.173.11.6515Baldwin TA, Hogquist KA, Jameson SC. The fourth way? Harnessing aggressive tendencies in the thymus. J Immunol. 2004;173(11):6515–6520. PMID: 15557139 https://doi.org/10.4049/JIMMUNOL.173.11.6515Lio CWJ, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity. 2008;28(1):100–111. PMID: 18199417 https://doi.org/10.1016/j.immuni.2007.11.021Lio CWJ, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity. 2008;28(1):100–111. PMID: 18199417 https://doi.org/10.1016/j.immuni.2007.11.021Fazilleau N, Bachelez H, Gougeon ML, Viguier M. Cutting edge: size and diversity of CD4+CD25high Foxp3+ regulatory T cell repertoire in humans: evidence for similarities and partial overlapping with CD4+CD25T cells. J Immunol. 2007;179(6):3412–3416. PMID: 17785774 https://doi.org/10.4049/jimmunol.179.6.3412Fazilleau N, Bachelez H, Gougeon ML, Viguier M. Cutting edge: size and diversity of CD4+CD25high Foxp3+ regulatory T cell repertoire in humans: evidence for similarities and partial overlapping with CD4+CD25T cells. J Immunol. 2007;179(6):3412–3416. PMID: 17785774 https://doi.org/10.4049/jimmunol.179.6.3412Caramalho Í, Nunes-Cabaço H, Foxall RB, Sousa AE. Regulatory T-cell development in the human thymus. Front Immunol. 2015;6:395. PMID: 26284077 https://doi.org/10.3389/fimmu.2015.00395Caramalho Í, Nunes-Cabaço H, Foxall RB, Sousa AE. Regulatory T-cell development in the human thymus. Front Immunol. 2015;6:395. PMID: 26284077 https://doi.org/10.3389/fimmu.2015.00395Chen WJ, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25naive T cells to CD4+CD25+ regulatory T cells by TGFbeta induction of transcription factor Foxp3. J Exp Med. 2003;198(12):1875–1886. PMID: 14676299 https://doi.org/10.1084/jem.20030152Chen WJ, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25naive T cells to CD4+CD25+ regulatory T cells by TGFbeta induction of transcription factor Foxp3. J Exp Med. 2003;198(12):1875–1886. PMID: 14676299 https://doi.org/10.1084/jem.20030152Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell. 2012;150(1):29–38. PMID: 22770213 https://doi.org/10.1016/J.CELL.2012.05.031Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell. 2012;150(1):29–38. PMID: 22770213 https://doi.org/10.1016/J.CELL.2012.05.031Cebula A, Seweryn M, Rempala GA, Pabla SS, McIndoe RA, Denning TL, et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature. 2013;497(7448):258–262. PMID: 23624374 https://doi.org/10.1038/NATURE12079Cebula A, Seweryn M, Rempala GA, Pabla SS, McIndoe RA, Denning TL, et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature. 2013;497(7448):258–262. PMID: 23624374 https://doi.org/10.1038/NATURE12079Zegarra-Ruiz DF, Kim DV, Norwood K., Kim M, Wu WJH, SaldanaMorales FB, et al. Thymic development of gut-microbiota-specific T cells. Nature. 2021;594(7863):413–417. PMID: 33981034 https://doi.org/10.1038/S41586-02103531-1Zegarra-Ruiz DF, Kim DV, Norwood K., Kim M, Wu WJH, SaldanaMorales FB, et al. Thymic development of gut-microbiota-specific T cells. Nature. 2021;594(7863):413–417. PMID: 33981034 https://doi.org/10.1038/S41586-02103531-1Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014;20(1):62–68. PMID: 24362934 https://doi.org/10.1038/NM.3432Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014;20(1):62–68. PMID: 24362934 https://doi.org/10.1038/NM.3432Wyss L, Stadinski BD, King CG, Schallenberg S, Mccarthy NI, Lee JY, et al. Affinity for self antigen selects Treg cells with distinct functional properties. Nat Immunol. 2016;17(9):1093– 1101. PMID: 27478940 https://doi.org/10.1038/NI.3522Wyss L, Stadinski BD, King CG, Schallenberg S, Mccarthy NI, Lee JY, et al. Affinity for self antigen selects Treg cells with distinct functional properties. Nat Immunol. 2016;17(9):1093– 1101. PMID: 27478940 https://doi.org/10.1038/NI.3522Thome JJC, Yudanin N, Ohmura Y, Kubota M, Grinshpun B, Sathaliyawala T, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014;159(4):814–828. PMID: 25417158 https://doi.org/10.1016/j.cell.2014.10.026Thome JJC, Yudanin N, Ohmura Y, Kubota M, Grinshpun B, Sathaliyawala T, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014;159(4):814–828. PMID: 25417158 https://doi.org/10.1016/j.cell.2014.10.026Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899–911. PMID: 19464196 https://doi.org/10.1016/j.immuni.2009.03.019Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899–911. PMID: 19464196 https://doi.org/10.1016/j.immuni.2009.03.019Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, Lee S, et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood. 2006;107(7):2830–2838. PMID: 16332974 https://doi.org/10.1182/BLOOD-2005-06-2403Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, Lee S, et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood. 2006;107(7):2830–2838. PMID: 16332974 https://doi.org/10.1182/BLOOD-2005-06-2403Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006;107(10):3925–3932. PMID: 16418326 https://doi.org/10.1182/blood2005-11-4502Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006;107(10):3925–3932. PMID: 16418326 https://doi.org/10.1182/blood2005-11-4502Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27(4):635–646. PMID: 17919943 https://doi.org/10.1016/j.immuni.2007.08.014Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27(4):635–646. PMID: 17919943 https://doi.org/10.1016/j.immuni.2007.08.014Дроков М.Ю., Паровичникова Е.Н., Кузьмина Л.А., Гальцева И.В., Васильева В.А., Михальцова Е.Д. и др. Роль гранзима В в популяции Т-регуляторных клеток у пациентов после трансплантации аллогенного костного мозга. Гематология и трансфузиология. 2016;61(1):32–37. https://doi.org/10.18821/0234-57302016-61-1-32-37Drokov MY, Parovichnikova EN, Kuzmina LA, Galtseva IV, Vasilieva VA, Mikhaltsova ED, et al. Role of granzyme B in T regulatory cells in patients after allogeneic stem cell transplantation. Gematologiya I Transfusiologiya. 2016;61(1):32–37. (In Russ.). https://doi.org/10.18821/0234-57302016-61-1-32-37Zhu Z, Zhang Y, Ye J, Wang X, Fu X, Yin Y, et al. IL-35 promoted STAT3 phosphorylation and IL-10 production in B cells, but its production was reduced in patients with coronary artery diseases. Hum Immunol. 2018;79(12):869– 875. PMID: 30316971 https://doi.org/10.1016/j.humimm.2018.10.009Zhu Z, Zhang Y, Ye J, Wang X, Fu X, Yin Y, et al. IL-35 promoted STAT3 phosphorylation and IL-10 production in B cells, but its production was reduced in patients with coronary artery diseases. Hum Immunol. 2018;79(12):869– 875. PMID: 30316971 https://doi.org/10.1016/j.humimm.2018.10.009Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190(7):995–1003. PMID: 10510089 https://doi.org/10.1084/JEM.190.7.995Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190(7):995–1003. PMID: 10510089 https://doi.org/10.1084/JEM.190.7.995Hawrylowicz CM, O’Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol. 2005;5(4):271–283. PMID: 15775993 https://doi.org/10.1038/NRI1589Hawrylowicz CM, O’Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol. 2005;5(4):271–283. PMID: 15775993 https://doi.org/10.1038/NRI1589Loser K, Apelt J, Voskort M, Mohaupt M, Balkow S, Schwarz T, et al. IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol. 2007;179(1):365–371. PMID: 17579057 https://doi.org/10.4049/jimmunol.179.1.365Loser K, Apelt J, Voskort M, Mohaupt M, Balkow S, Schwarz T, et al. IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol. 2007;179(1):365–371. PMID: 17579057 https://doi.org/10.4049/jimmunol.179.1.365Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA. 2003;100(19):10878–10883. PMID: 12949259 https://doi.org/10.1073/PNAS.1834400100Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA. 2003;100(19):10878–10883. PMID: 12949259 https://doi.org/10.1073/PNAS.1834400100Akkaya B, Oya Y, Akkaya M, Al Souz J, Holstein AH, Kamenyeva O, et al. Regulatory T cells mediate specific suppression by depleting peptide-MHC class II from dendritic cells. Nat Immunol. 2019;20(2):218–231. PMID: 30643268 https://doi.org/10.1038/S41590-0180280-2Akkaya B, Oya Y, Akkaya M, Al Souz J, Holstein AH, Kamenyeva O, et al. Regulatory T cells mediate specific suppression by depleting peptide-MHC class II from dendritic cells. Nat Immunol. 2019;20(2):218–231. PMID: 30643268 https://doi.org/10.1038/S41590-0180280-2Chinen T, Kannan AK, Levine AG, Fan X, Klein U, Zheng Y, et al. An essential role for the IL-2 receptor in T reg cell function. Nat Immunol. 2016;17(11):1322–1333. PMID: 27595233 https://doi.org/10.1038/NI.3540Chinen T, Kannan AK, Levine AG, Fan X, Klein U, Zheng Y, et al. An essential role for the IL-2 receptor in T reg cell function. Nat Immunol. 2016;17(11):1322–1333. PMID: 27595233 https://doi.org/10.1038/NI.3540Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol. 2010;185(4):1993–1998. PMID: 20686167 https://doi.org/10.4049/jimmunol.1000108Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol. 2010;185(4):1993–1998. PMID: 20686167 https://doi.org/10.4049/jimmunol.1000108Schwarz A, Schumacher M, Pfaff D, Schumacher K, Jarius S, Balint B, et al. Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis. J Immunol. 2013;190(10):4965–4970. PMID: 23576680 https://doi.org/10.4049/JIMMUNOL.1203224Schwarz A, Schumacher M, Pfaff D, Schumacher K, Jarius S, Balint B, et al. Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis. J Immunol. 2013;190(10):4965–4970. PMID: 23576680 https://doi.org/10.4049/JIMMUNOL.1203224Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–1561. PMID: 19282026 https://doi.org/10.1016/S01406736(09)60237-3Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–1561. PMID: 19282026 https://doi.org/10.1016/S01406736(09)60237-3Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1. PMID: 25529383 https://doi.org/10.1016/J.BBMT.2014.12.001Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1. PMID: 25529383 https://doi.org/10.1016/J.BBMT.2014.12.001Zeiser R, Blazar BR. Acute graftversus-host disease – biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167–2179. PMID: 29171820 https://doi.org/10.1056/NEJMRA1609337Zeiser R, Blazar BR. Acute graftversus-host disease – biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167–2179. PMID: 29171820 https://doi.org/10.1056/NEJMRA1609337Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The Biology of chronic graft-versus-host disease: a task force report from the National institutes of health consensus development project on criteria for clinical trials in chronic graftversus-host disease. Biol Blood Marrow Transplant. 2017;23(2):211–234. PMID: 27713092 https://doi.org/10.1016/J.BBMT.2016.09.023Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The Biology of chronic graft-versus-host disease: a task force report from the National institutes of health consensus development project on criteria for clinical trials in chronic graftversus-host disease. Biol Blood Marrow Transplant. 2017;23(2):211–234. PMID: 27713092 https://doi.org/10.1016/J.BBMT.2016.09.023Schneider M, Munder M, Karakhanova S, Ho AD, Goerner M. The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation. Clin Lab Haematol. 2006;28(6):382–390. PMID: 17105491 https://doi.org/10.1111/J.1365-2257.2006.00825.XSchneider M, Munder M, Karakhanova S, Ho AD, Goerner M. The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation. Clin Lab Haematol. 2006;28(6):382–390. PMID: 17105491 https://doi.org/10.1111/J.1365-2257.2006.00825.XFujioka T, Tamaki H, Ikegame K, Yoshihara S, Taniguchi K, Kaida K, et al. Frequency of CD4(+)FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant. 2013;48(6):859–864. PMID: 23165499 https://doi.org/10.1038/BMT.2012.232Fujioka T, Tamaki H, Ikegame K, Yoshihara S, Taniguchi K, Kaida K, et al. Frequency of CD4(+)FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant. 2013;48(6):859–864. PMID: 23165499 https://doi.org/10.1038/BMT.2012.232Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127(5):646–657. PMID: 26670634 https://doi.org/10.1182/BLOOD-2015-10-672345Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127(5):646–657. PMID: 26670634 https://doi.org/10.1182/BLOOD-2015-10-672345Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GVHD. Blood. 2006;107(4):1717–1723. PMID: 16278306 https://doi.org/10.1182/BLOOD-2005-06-2529Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GVHD. Blood. 2006;107(4):1717–1723. PMID: 16278306 https://doi.org/10.1182/BLOOD-2005-06-2529Forbes GM, Erber WN, Herrmann RP, Davies JM, Collins BJ. Immunohistochemical changes in sigmoid colon after allogeneic and autologous bone marrow transplantation. J Clin Pathol. 1995;48(4):308–313. PMID: 7615847 https://doi.org/10.1136/JCP.48.4.308Forbes GM, Erber WN, Herrmann RP, Davies JM, Collins BJ. Immunohistochemical changes in sigmoid colon after allogeneic and autologous bone marrow transplantation. J Clin Pathol. 1995;48(4):308–313. PMID: 7615847 https://doi.org/10.1136/JCP.48.4.308Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006;108(4):1291–1297. PMID: 16627754 https://doi.org/10.1182/BLOOD-2006-02-003996Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006;108(4):1291–1297. PMID: 16627754 https://doi.org/10.1182/BLOOD-2006-02-003996Yang K, Fan Z-P, Liu Q-F, Zhang Y. Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28(4):537–541. PMID: 18495584Yang K, Fan Z-P, Liu Q-F, Zhang Y. Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28(4):537–541. PMID: 18495584Le Texier L, Lineburg KE, Cao B, McDonald-Hyman C, Mouttie LLEl, Nicholls J, et al. Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. JCI Insight. 2016;1(15). PMID: 27699243 https://doi.org/10.1172/JCI.INSIGHT.86850Le Texier L, Lineburg KE, Cao B, McDonald-Hyman C, Mouttie LLEl, Nicholls J, et al. Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. JCI Insight. 2016;1(15). PMID: 27699243 https://doi.org/10.1172/JCI.INSIGHT.86850Fujisaki J, Wu J, Carlson AL, Silberstein L, Putheti P, Larocca R, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature. 2011;474(7350):216–219. PMID: 21654805 https://doi.org/10.1038/NATURE10160Fujisaki J, Wu J, Carlson AL, Silberstein L, Putheti P, Larocca R, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature. 2011;474(7350):216–219. PMID: 21654805 https://doi.org/10.1038/NATURE10160Hirata Y, Furuhashi K, Ishii H, Li HW, Pinho S, Ding L, et al. CD150high bone marrow Tregs maintain hematopoietic stem cell quiescence and immune privilege via adenosine. Cell Stem Cell. 2018;22(3):445–453.e5. PMID: 29456159 https://doi.org/10.1016/J.STEM.2018.01.017Hirata Y, Furuhashi K, Ishii H, Li HW, Pinho S, Ding L, et al. CD150high bone marrow Tregs maintain hematopoietic stem cell quiescence and immune privilege via adenosine. Cell Stem Cell. 2018;22(3):445–453.e5. PMID: 29456159 https://doi.org/10.1016/J.STEM.2018.01.017Mahr B, Pilat N, Maschke S, Granofszky N, Schwarz C, Unger L, et al. Regulatory T cells promote natural killer cell education in mixed Chimeras. Am J Transplant. 2017;17(12):3049– 3059. PMID: 28489338 https://doi.org/10.1111/AJT.14342Mahr B, Pilat N, Maschke S, Granofszky N, Schwarz C, Unger L, et al. Regulatory T cells promote natural killer cell education in mixed Chimeras. Am J Transplant. 2017;17(12):3049– 3059. PMID: 28489338 https://doi.org/10.1111/AJT.14342Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, et al. Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. Sci Rep. 2016;6:39247. PMID: 27976733 https://doi.org/10.1038/SREP39247Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, et al. Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. Sci Rep. 2016;6:39247. PMID: 27976733 https://doi.org/10.1038/SREP39247Nair VS, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018;96(1):21–33. PMID: 29359507 https://doi.org/10.1111/IMCB.1003Nair VS, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018;96(1):21–33. PMID: 29359507 https://doi.org/10.1111/IMCB.1003Idris SZ, Hassan N, Lee LJ, Md Noor S, Osman R, Abdul-Jalil M, et al. Increased regulatory T cells in acute lymphoblastic leukaemia patients. Hematology. 2016;21(4):206–212. PMID: 26907959 https://doi.org/10.1080/10245332.2015.1101965Idris SZ, Hassan N, Lee LJ, Md Noor S, Osman R, Abdul-Jalil M, et al. Increased regulatory T cells in acute lymphoblastic leukaemia patients. Hematology. 2016;21(4):206–212. PMID: 26907959 https://doi.org/10.1080/10245332.2015.1101965Wan Y, Zhang C, Xu Y, Wang M, Rao Q, Xing H, et al. Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia. BMC Cancer. 2020;20(1):472. PMID: 32456622 https://doi.org/10.1186/S12885-020-06961-8Wan Y, Zhang C, Xu Y, Wang M, Rao Q, Xing H, et al. Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia. BMC Cancer. 2020;20(1):472. PMID: 32456622 https://doi.org/10.1186/S12885-020-06961-8Edinger M, Hoffmann P, Ermann J, Drago K, Garrison Fathman C, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144–1450. PMID: 12925844 https://doi.org/10.1038/NM915Edinger M, Hoffmann P, Ermann J, Drago K, Garrison Fathman C, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144–1450. PMID: 12925844 https://doi.org/10.1038/NM915Meyer EH, Hoeg R, Moroz A, Xie BJ, Wu HH, Pawar R, et al. 88 – Orca-T, a precision Treg-engineered donor product, in myeloablative HLA-matched transplantation prevents acute GVHD with less immunosuppression in an early multicenter experience. Transplant Cell Ther. 2021;27(3Suppl):S84–S85. https://doi.org/10.1016/S2666-6367(21)00114-7Meyer EH, Hoeg R, Moroz A, Xie BJ, Wu HH, Pawar R, et al. 88 – Orca-T, a precision Treg-engineered donor product, in myeloablative HLA-matched transplantation prevents acute GVHD with less immunosuppression in an early multicenter experience. Transplant Cell Ther. 2021;27(3Suppl):S84–S85. https://doi.org/10.1016/S2666-6367(21)00114-7Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLAhaploidentical transplantation. Blood. 2011;117(14):3921–3928. PMID: 21292771 https://doi.org/10.1182/BLOOD-201010-311894Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLAhaploidentical transplantation. Blood. 2011;117(14):3921–3928. PMID: 21292771 https://doi.org/10.1182/BLOOD-201010-311894Pierini A, Ruggeri L, Carotti A, Falzetti F, Saldi S, Terenzi A, et al. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. Blood Adv. 2021;5(5):1199–2208. PMID: 33646302 https://doi.org/10.1182/bloodadvances.2020003739Pierini A, Ruggeri L, Carotti A, Falzetti F, Saldi S, Terenzi A, et al. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. Blood Adv. 2021;5(5):1199–2208. PMID: 33646302 https://doi.org/10.1182/bloodadvances.2020003739Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation. 2006;82(4):550–557. PMID: 16926600 https://doi.org/10.1097/01.TP.0000229473.95202.50Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation. 2006;82(4):550–557. PMID: 16926600 https://doi.org/10.1097/01.TP.0000229473.95202.50Pascual J, Bloom D, Torrealba J, Brahmbhatt R, Chang Z, Sollinger HW, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant. 2008;8(7):1529–1536. PMID: 18510645 https://doi.org/10.1111/J.16006143.2008.02260.XPascual J, Bloom D, Torrealba J, Brahmbhatt R, Chang Z, Sollinger HW, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant. 2008;8(7):1529–1536. PMID: 18510645 https://doi.org/10.1111/J.16006143.2008.02260.XDemirkiran A, Sewgobind VDKD, Van Der Weijde J, Kok A, Baan CC, Kwekkeboom J, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation. 2009;87(7):1062–1068. PMID: 19352129 https://doi.org/10.1097/TP.0B013E31819D2032Demirkiran A, Sewgobind VDKD, Van Der Weijde J, Kok A, Baan CC, Kwekkeboom J, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation. 2009;87(7):1062–1068. PMID: 19352129 https://doi.org/10.1097/TP.0B013E31819D2032He X, Smeets RL, Koenen HJPM, Vink PM, Wagenaars J, Boots AMH, et al. Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation. Am J Transplant. 2011;11(3):439–449. PMID: 21342445 https://doi.org/10.1111/J.1600-6143.2010.03413.XHe X, Smeets RL, Koenen HJPM, Vink PM, Wagenaars J, Boots AMH, et al. Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation. Am J Transplant. 2011;11(3):439–449. PMID: 21342445 https://doi.org/10.1111/J.1600-6143.2010.03413.XScottà C, Fanelli G, Hoong SJ, Romano M, Lamperti EN, Sukthankar M, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. 2016;101(1):91–100. PMID: 26471483 https://doi.org/10.3324/haematol.2015.128934Scottà C, Fanelli G, Hoong SJ, Romano M, Lamperti EN, Sukthankar M, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. 2016;101(1):91–100. PMID: 26471483 https://doi.org/10.3324/haematol.2015.128934Landwehr-Kenzel S, Zobel A, Schmitt-Knosalla I, Forke A, Hoffmann H, Schmueck-Henneresse M, et al. Cyclosporine A but not corticosteroids support efficacy of ex vivo expanded, adoptively transferred human Tregs in GVHD. Front Immunol. 2021;12:716629. PMID: 34707604 https://doi.org/10.3389/FIMMU.2021.716629Landwehr-Kenzel S, Zobel A, Schmitt-Knosalla I, Forke A, Hoffmann H, Schmueck-Henneresse M, et al. Cyclosporine A but not corticosteroids support efficacy of ex vivo expanded, adoptively transferred human Tregs in GVHD. Front Immunol. 2021;12:716629. PMID: 34707604 https://doi.org/10.3389/FIMMU.2021.716629Zhang P, Tey SK, Koyama M, Kuns RD, Olver SD, Lineburg KE, et al. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. J Immunol. 2013;191(10):5291–5303. PMID: 24123683 https://doi.org/10.4049/jimmunol.1301181Zhang P, Tey SK, Koyama M, Kuns RD, Olver SD, Lineburg KE, et al. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. J Immunol. 2013;191(10):5291–5303. PMID: 24123683 https://doi.org/10.4049/jimmunol.1301181Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157. PMID: 24225944 https://doi.org/10.1126/scitranslmed.3006960Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157. PMID: 24225944 https://doi.org/10.1126/scitranslmed.3006960Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant. 2010;10(9):2132–2141. PMID: 20883548 https://doi.org/10.1111/J.1600-6143.2010.03210.XGurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant. 2010;10(9):2132–2141. PMID: 20883548 https://doi.org/10.1111/J.1600-6143.2010.03210.XFeng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008;111(7):3675– 3683. PMID: 18250226 https://doi.org/10.1182/BLOOD-2008-01-130146Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008;111(7):3675– 3683. PMID: 18250226 https://doi.org/10.1182/BLOOD-2008-01-130146Suárez A, López P, Gómez J, Gutiérrez C. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis. 2006;65(11):1512–1517. PMID: 16606650 https://doi.org/10.1136/ARD.2005.049924Suárez A, López P, Gómez J, Gutiérrez C. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis. 2006;65(11):1512–1517. PMID: 16606650 https://doi.org/10.1136/ARD.2005.049924Seissler N, Schmitt E, Hug F, Sommerer C, Zeier M, Schaier M, et al. Methylprednisolone treatment increases the proportion of the highly suppressive HLA-DR(+)-Tregcells in transplanted patients. Transpl Immunol. 2012;27(4):157–161. PMID: 23022208 https://doi.org/10.1016/J.TRIM.2012.09.003Seissler N, Schmitt E, Hug F, Sommerer C, Zeier M, Schaier M, et al. Methylprednisolone treatment increases the proportion of the highly suppressive HLA-DR(+)-Tregcells in transplanted patients. Transpl Immunol. 2012;27(4):157–161. PMID: 23022208 https://doi.org/10.1016/J.TRIM.2012.09.003Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116(1):129–139. PMID: 20424188 https://doi.org/10.1182/BLOOD-2009-12-257253Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116(1):129–139. PMID: 20424188 https://doi.org/10.1182/BLOOD-2009-12-257253Cooper ML, Choi J, Karpova D, Vij K, Ritchey J, Schroeder MA, et al. Azacitidine mitigates graft-versus-host disease via differential effects on the proliferation of T effectors and natural regulatory T cells in vivo. J Immunol. 2017;198(9):3746–3754. PMID: 28330901 https://doi.org/10.4049/JIMMUNOL.1502399Cooper ML, Choi J, Karpova D, Vij K, Ritchey J, Schroeder MA, et al. Azacitidine mitigates graft-versus-host disease via differential effects on the proliferation of T effectors and natural regulatory T cells in vivo. J Immunol. 2017;198(9):3746–3754. PMID: 28330901 https://doi.org/10.4049/JIMMUNOL.1502399Nguyen VH, Zeiser R, DaSilva DL, Chang DS, Beilhack A, Contag CH, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versushost disease following allogeneic transplantation. Blood. 2007;109(6):2649–2656. PMID: 17095616 https://doi.org/10.1182/BLOOD-2006-08-044529Nguyen VH, Zeiser R, DaSilva DL, Chang DS, Beilhack A, Contag CH, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versushost disease following allogeneic transplantation. Blood. 2007;109(6):2649–2656. PMID: 17095616 https://doi.org/10.1182/BLOOD-2006-08-044529Riegel C, Boeld TJ, Doser K, Huber E, Hoffmann P, Edinger M. Efficient treatment of murine acute GVHD by in vitro expanded donor regulatory T cells. Leukemia. 2020;34(3):895–908. PMID: 31719679 https://doi.org/10.1038/S41375-019-0625-3Riegel C, Boeld TJ, Doser K, Huber E, Hoffmann P, Edinger M. Efficient treatment of murine acute GVHD by in vitro expanded donor regulatory T cells. Leukemia. 2020;34(3):895–908. PMID: 31719679 https://doi.org/10.1038/S41375-019-0625-3Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, et al. First-inman clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127T regulatory cells. Clin Immunol. 2009;133(1):22–26. PMID: 19559653 https://doi.org/10.1016/J.CLIM.2009.06.001Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, et al. First-inman clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127T regulatory cells. Clin Immunol. 2009;133(1):22–26. PMID: 19559653 https://doi.org/10.1016/J.CLIM.2009.06.001Marinelli Busilacchi E, Costantini A, Viola N, Costantini B, Olivieri J, Butini L, et al. Immunomodulatory effects of tyrosine kinase inhibitor in vitro and in vivo study. Biol Blood Marrow Transplant. 2018;24(2):267–275. PMID: 29128554 https://doi.org/10.1016/J.BBMT.2017.10.039Marinelli Busilacchi E, Costantini A, Viola N, Costantini B, Olivieri J, Butini L, et al. Immunomodulatory effects of tyrosine kinase inhibitor in vitro and in vivo study. Biol Blood Marrow Transplant. 2018;24(2):267–275. PMID: 29128554 https://doi.org/10.1016/J.BBMT.2017.10.039Theil A, Tuve S, Oelschlägel U, Maiwald A, Döhler D, Oßmann D, et al. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy. 2015;17(4):473–486. PMID: 25573333 https://doi.org/10.1016/J.JCYT.2014.11.005Theil A, Tuve S, Oelschlägel U, Maiwald A, Döhler D, Oßmann D, et al. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy. 2015;17(4):473–486. PMID: 25573333 https://doi.org/10.1016/J.JCYT.2014.11.005Lim JY, Im KIl, Song Y, Kim N, Nam YS, Jeon YW, et al. Third-party regulatory T cells prevent murine acute graft-versus-host disease. Korean J Intern Med. 2018;33(5):980–989. PMID: 29050459 https://doi.org/10.3904/KJIM.2016.319Lim JY, Im KIl, Song Y, Kim N, Nam YS, Jeon YW, et al. Third-party regulatory T cells prevent murine acute graft-versus-host disease. Korean J Intern Med. 2018;33(5):980–989. PMID: 29050459 https://doi.org/10.3904/KJIM.2016.319Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, David EA, et al. Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood. 2001;98(9):2736–2744. PMID: 11675346 https://doi.org/10.1182/BLOOD.V98.9.2736Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, David EA, et al. Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood. 2001;98(9):2736–2744. PMID: 11675346 https://doi.org/10.1182/BLOOD.V98.9.2736Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172(7):3983–3988. PMID: 15034008 https://doi.org/10.4049/JIMMUNOL.172.7.3983Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172(7):3983–3988. PMID: 15034008 https://doi.org/10.4049/JIMMUNOL.172.7.3983Matsuoka KI, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra43. PMID: 23552371 https://doi.org/10.1126/SCITRANSLMED.3005265Matsuoka KI, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra43. PMID: 23552371 https://doi.org/10.1126/SCITRANSLMED.3005265Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014;20(8):2215–2225. PMID: 24573552 https://doi.org/10.1158/1078-0432.CCR-13-3205Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014;20(8):2215–2225. PMID: 24573552 https://doi.org/10.1158/1078-0432.CCR-13-3205Morales JM M, Münch N, Peter K, Freund D, Oelschlägel U, Hölig K, et al. Automated clinical grade expansion of regulatory T cells in a fully closed system. Front Immunol. 2019;10:38. PMID: 30778344 https://doi.org/10.3389/FIMMU.2019.00038Morales JM M, Münch N, Peter K, Freund D, Oelschlägel U, Hölig K, et al. Automated clinical grade expansion of regulatory T cells in a fully closed system. Front Immunol. 2019;10:38. PMID: 30778344 https://doi.org/10.3389/FIMMU.2019.00038Someya K, Nakatsukasa H, Ito M, Kondo T, Tateda K, Akanuma T, et al. Improvement of Foxp3 stability through CNS2 demethylation by TET enzyme induction and activation. Int Immunol. 2017;29(8):365–375. PMID: 29048538 https://doi.org/10.1093/INTIMM/DXX049Someya K, Nakatsukasa H, Ito M, Kondo T, Tateda K, Akanuma T, et al. Improvement of Foxp3 stability through CNS2 demethylation by TET enzyme induction and activation. Int Immunol. 2017;29(8):365–375. PMID: 29048538 https://doi.org/10.1093/INTIMM/DXX049Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitroexpanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199(11):1455–1465. PMID: 15184499 https://doi.org/10.1084/JEM.20040139Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitroexpanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199(11):1455–1465. PMID: 15184499 https://doi.org/10.1084/JEM.20040139Stephens LA, Malpass KH, Anderton SM. Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur J Immunol. 2009;39(4):1108–1117. PMID: 19350586 https://doi.org/10.1002/EJI.200839073Stephens LA, Malpass KH, Anderton SM. Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur J Immunol. 2009;39(4):1108–1117. PMID: 19350586 https://doi.org/10.1002/EJI.200839073Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graftversus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112(11):1688–1696. PMID: 14660744 https://doi.org/10.1172/JCI17702Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graftversus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112(11):1688–1696. PMID: 14660744 https://doi.org/10.1172/JCI17702Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3(83):83ra42. PMID: 21593402 https://doi.org/10.1126/SCITRANSLMED.3002076Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3(83):83ra42. PMID: 21593402 https://doi.org/10.1126/SCITRANSLMED.3002076Raffin C, Vo LT, Bluestone JA. Treg cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20(3):158–172. PMID: 31811270 https://doi.org/10.1038/S41577-0190232-6Raffin C, Vo LT, Bluestone JA. Treg cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20(3):158–172. PMID: 31811270 https://doi.org/10.1038/S41577-0190232-6MacDonald KG, Hoeppli RE, Huang Q, Gillies J, Luciani DS, Orban PC, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126(4):1413–1424. PMID: 26999600 https://doi.org/10.1172/JCI82771MacDonald KG, Hoeppli RE, Huang Q, Gillies J, Luciani DS, Orban PC, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126(4):1413–1424. PMID: 26999600 https://doi.org/10.1172/JCI82771

The authors declare that there are no conflicts of interest present.